Payment overview · 2025
General Payments
$459.14
22 reported records · 8 companies
Healthcare provider profile · identity verified
Mark C Stine, DO
Allopathic & Osteopathic Physicians|General Practice · LARGO, FL · NPI 1174563449
Verified facts
What the public records show
CMS Open Payments records show Mark C Stine, DO received $459.14 in general payments during 2025 across 22 reported records.
Gilead Sciences, Inc. accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $125.94 | 27.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $115.67 | 25.2% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $71.21 | 15.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.04 | 8.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $35.07 | 7.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $28.31 | 6.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.24 | 5.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.66 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $459.14 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $97.13 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.85 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.85 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.04 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $35.07 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $28.31 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.54 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.54 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 111 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
111 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 312 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 247 | 69 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 218 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 206 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 199 | 72 |
| Lisinopril | Lisinopril | 198 | 56 |
| Losartan Potassium | Losartan Potassium | 166 | 52 |
| Prednisone | Prednisone | 144 | 87 |
| Metformin Hcl | Metformin Hcl | 141 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 37 |
| Alprazolam | Alprazolam | 121 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 38 |
| Eliquis | Apixaban | 111 | 23 |
| Gabapentin | Gabapentin | 111 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 34 |
| Azithromycin | Azithromycin | 102 | 78 |
| Omeprazole | Omeprazole | 102 | 30 |
| Tramadol Hcl | Tramadol Hcl | 95 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 28 |
| Potassium Chloride | Potassium Chloride | 91 | 35 |
| Trazodone Hcl | Trazodone Hcl | 91 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 20 |
| Carvedilol | Carvedilol | 85 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 24 |
| Furosemide | Furosemide | 82 | 33 |
| Meloxicam | Meloxicam | 77 | 31 |
| Simvastatin | Simvastatin | 66 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 17 |
| Dexamethasone | Dexamethasone | 56 | 29 |
| Ezetimibe | Ezetimibe | 51 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 48 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 32 |
| Temazepam | Temazepam | 47 | suppressed |
| Baclofen | Baclofen | 46 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | suppressed |
| Finasteride | Finasteride | 43 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 19 |
| Allopurinol | Allopurinol | 42 | 13 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Ramipril | Ramipril | 42 | 12 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Nifedipine Er | Nifedipine | 41 | 13 |
| Naproxen | Naproxen | 40 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 37 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | 11 |
| Glipizide | Glipizide | 31 | 11 |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 13 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 15 |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Famotidine | Famotidine | 26 | 14 |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 15 |
| Fluconazole | Fluconazole | 21 | 14 |
| Glipizide Er | Glipizide | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 16 |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $459.14 · 22 records | Gilead Sciences, Inc. | AIRSUPRA, ELIQUIS, FREESTYLE LIBRE 3, JARDIANCE, KISUNLA, MOUNJARO, QULIPTA, UBRELVY, VRAYLAR, Veozah, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error